Kiran Bath, MD
Neuromusculoskeletal Medicine & OMM · Fullerton, CANPI 1689831380
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 60.4% of it on its own, with 45 other manufacturers making up the rest. Reporting peaked in 2021 at $6,152 and has fallen 79.2% since, to $1,279 in 2025. Among neuromusculoskeletal medicine & omm clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 429 payments — averaging $46.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Abbott$2K
- Novartis$1K
- AstraZeneca$464
- CSL Behring$403
- UCB, Inc.$318
- plus $4K from 40 others
Across 28 payments — averaging $5199.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$68K
- Sanofi$52K
- Biohaven Pharmaceuticals, Inc.$17K
- Novartis$8K
What the payments were for
- Speaking & faculty fees$10,02550%
- Travel & lodging$2,09410%
- Food & beverage$7,74739%
- Education$2121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,078 in reported general payments places this provider in the 95th percentile of 113 neuromusculoskeletal medicine & omm providers in California.
See all neuromusculoskeletal medicine & omm providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvgartEfgartigimod Alfa-Fcab | 11 | $515,397 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 26 | $118,777 |
| CopaxoneGlatiramer Acetate | 11 | $76,689 |
| RytaryCarbidopa/Levodopa | 16 | $23,430 |
| NamzaricMemantine Hcl/Donepezil Hcl | 25 | $22,717 |
| LeqembiLecanemab-Irmb | 21 | $20,076 |
| Rivastigmine | 63 | $14,718 |
| Memantine Hcl | 203 | $12,791 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,925 |
| Memantine Hcl ErMemantine Hcl | 65 | $8,621 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 202 | $7,062 |
| Donepezil Hcl | 482 | $4,815 |
| RivastigmineRivastigmine Tartrate | 67 | $4,488 |
| Galantamine Hbr | 56 | $4,396 |
| Lacosamide | 35 | $4,363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Argenx US, Inc.Vyvgart | $252 | $515,39711 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $34 | $118,77726 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $180 | $76,68911 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $42 | $25,88236 claims |
| AbbVieNamzaric | $12,136 | $22,71725 claims |
| Eisai Inc.Leqembi | $241 | $20,07621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 113 neuromusculoskeletal medicine & omm providers in California.
Other neuromusculoskeletal medicine & omm in Fullerton
- Raffy MirzayanBaldwin Park$458K
- Dean MatsudaLos Angeles$452K
- Scott ShoemakerSan Diego$49K
- Narendra GurbaniBellflower$40K
- Richard DellBellflower$15K
- Emil DionysianAnaheim$14K
- Richard HartmanSanta Barbara$6K
- Neil HarnessAnaheim$4K
- William OharaSan Diego$4K
- Gary RosenbergLos Angeles$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.